Safety, Tolerability, and Pharmacokinetics of Single Rising s.c. (Stage 1) and i.v. (Stage 2) Doses of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers (Double-blind, Randomized, Placebo-controlled Within Dose Groups)
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Ankylosing spondylitis; Asthma; Crohn's disease; Psoriasis
- Focus Adverse reactions
- Sponsors AbbVie; Boehringer Ingelheim
- 05 Jul 2017 Status changed from active, no longer recruiting to completed.
- 16 Nov 2016 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
- 16 Nov 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2017.